Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the
Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO
On April 29, 2021, Mountain View, California-based startup Ceribell, Inc. announced the completion of a $53 million Series C financing,
Continue Reading Ceribell Announces Completion of $53 Million Series C Financing for Portable EEG that can Diagnose Seizures in Minutes
Capsida Biotherapeutics Inc.—a Thousand Oaks, CA-based emerging biotechnology company—recently emerged from stealth mode with $ 140 million in start-up capital
Continue Reading Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies
Bigfoot Biomedical®, a Milpitas, CA emerging company, recently announced that it has secured new financing of up to $57
Continue Reading Bigfoot Biomedical® Secures up to $57 Million in Financing from Madryn Asset Management
Founders of emerging companies must decide early on in their company’s growth cycle whether to require employees to assign their
Continue Reading IP Assignment Considerations for Emerging Companies
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company
Continue Reading The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
Centripetal Networks, Inc. (“Centripetal”), one of the fastest growing innovators in the cybersecurity space, leveraged its patent portfolio against Cisco
Continue Reading Lessons Learned From Centripetal’s Multi-Billion Dollar Damages Award Against Cisco
Founders routinely need to disclose their groundbreaking technologies to third party investors, suitors, collaborators, peers, consultants and others in order
Continue Reading Key Considerations Regarding Early Disclosures and Patent Protection